Takeda Pharmaceutical Co. $TAK Shares Bought by QRG Capital Management Inc.

QRG Capital Management Inc. grew its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 27.3% during the first quarter, Holdings Channel.com reports. The firm owned 367,688 shares of the company’s stock after acquiring an additional 78,958 shares during the period. QRG Capital Management Inc.’s holdings in Takeda Pharmaceutical were worth $6,810,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Private Trust Co. NA grew its stake in shares of Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after purchasing an additional 783 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after buying an additional 1,684 shares during the last quarter. SHP Wealth Management acquired a new stake in Takeda Pharmaceutical in the fourth quarter valued at $42,000. Caitong International Asset Management Co. Ltd raised its stake in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after buying an additional 2,328 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TAK. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Wall Street Zen downgraded Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Finally, Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Down 0.2%

Shares of TAK stock opened at $16.73 on Monday. The business’s fifty day moving average price is $16.09 and its 200 day moving average price is $16.87. The firm has a market capitalization of $53.26 billion, a PE ratio of 42.91 and a beta of -0.07. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 0.94 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.